Thrombospondin type-1 domain-containing protein 7B (THSD7B)

Thrombospondin type-1 domain-containing protein 7B (THSD7B) is a predicted membrane component containing thrombospondin type-1 domains, encoded by the THSD7B gene on chromosome 2 (2q22.1)[1][11]. This protein is predicted to be involved in organization of the actin cytoskeleton, cell adhesion, post-translational protein modification, and potentially glycosylation processes[1][3][8][10]. Mutations in THSD7B have been associated with familial lung adenocarcinoma, prostate cancer, and other malignancies, mostly via effects on cellular adhesion, invasion, metastasis, and by modulating immune-related pathways[3]. THSD7B is not a well-established therapeutic target, and no approved drugs directly target this protein. Its closest paralog is THSD7A, and it may interact with SPON (spondin) family proteins and angiogenesis-regulating proteins such as THBS1[3]. No molecular function is fully validated, but experimental and computational data indicate disease relevance through its roles in the cytoskeleton and extracellular matrix interactions[2][7][8]. No specific safety or monitoring concerns are reported, though disease-associated mutations may guide future biomarker or risk stratification efforts[3].

Other names

KIAA1679THSD7Bthrombospondin, type I, domain containing 7Bthrombospondin type-1 domain-containing protein 7B

None established for direct drug targeting; disease-associated mutations potentially impact cytoskeletal regulation, cell adhesion, and immune response